The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody

被引:67
作者
Syme, RM
Bruno, TF
Kozel, TR
Mody, CH
机构
[1] Univ Calgary, Dept Microbiol & Infect Dis, Div Pulm Med, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Dept Internal Med, Calgary, AB T2N 4N1, Canada
[3] Univ Nevada, Dept Microbiol, Reno, NV 59557 USA
关键词
D O I
10.1128/IAI.67.9.4620-4627.1999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cell-mediated immunity is critical for the host defense to Cryptococus neoformans, as demonstrated by numerous animal studies and the prevalence of the infection in AIDS patients, Previous studies have established that the polysaccharide capsule contributes to the virulence of C, neoformans by suppressing T-lymphocyte proliferation, which reflects the clonal expansion of T lymphocytes that is a hallmark of cell-mediated Immunity. The present studies were performed to identify the major mechanism by which polysaccharide impairs lymphocyte proliferation, since capsular polysaccharide has the potential to affect the development of T-lymphocyte responses by stimulating production of interleukin-10 (IL-10), inhibiting phagocytosis, and inducing shedding of cell surface receptors, We demonstrate that polysaccharide inhibits lymphocyte proliferation predominantly by blocking uptake of C. neoformans, which is crucial for subsequent lymphocyte proliferation. In addition, we show that polysaccharide did not suppress lymphocyte proliferation via an IL-10-dependent mechanism, nor did it affect critical surface receptor interactions on the T cell or antigen-presenting cell. Having established that polysaccharide impairs phagocytosis, we performed studies to determine whether opsonization with human serum or with anticapsular antibody could reverse this effect. Impaired uptake and lymphocyte proliferation that were induced by polysaccharide can be enhanced through opsonization with monoclonal antibodies or human serum, suggesting that antipolysaccharide antibodies might enhance the host defense by restoring uptake of the organism and subsequent presentation to T lymphocytes, These studies support the therapeutic potential of stimulating cell-mediated immunity to C, neoformans,vith anticapsular antibody.
引用
收藏
页码:4620 / 4627
页数:8
相关论文
共 51 条
[1]   ROLE OF TUMOR-NECROSIS-FACTOR AND GAMMA-INTERFERON IN ACQUIRED-RESISTANCE TO CRYPTOCOCCUS-NEOFORMANS IN THE CENTRAL-NERVOUS-SYSTEM OF MICE [J].
AGUIRRE, K ;
HAVELL, EA ;
GIBSON, GW ;
JOHNSON, LL .
INFECTION AND IMMUNITY, 1995, 63 (05) :1725-1731
[2]   BIOMOLECULAR EVENTS INVOLVED IN ANTICRYPTOCOCCAL RESISTANCE IN THE BRAIN [J].
BLASI, E ;
BARLUZZI, R ;
MAZZOLLA, R ;
PITZURRA, L ;
PULITI, M ;
SALEPPICO, S ;
BISTONI, F .
INFECTION AND IMMUNITY, 1995, 63 (04) :1218-1222
[3]   QUANTITATIVE-ANALYSIS OF PHAGOCYTOSIS AND KILLING OF CRYPTOCOCCUS-NEOFORMANS BY HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY FLOW-CYTOMETRY [J].
CHAKA, W ;
SCHARRINGA, J ;
VERHEUL, AFM ;
VERHOEF, J ;
VANSTRIJP, AG ;
HOEPELMAN, IM .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1995, 2 (06) :753-759
[4]   CRYPTOCOCCAL INFECTION IN AIDS [J].
COKER, RJ .
INTERNATIONAL JOURNAL OF STD & AIDS, 1992, 3 (03) :168-172
[5]   ENCAPSULATION OF CRYPTOCOCCUS-NEOFORMANS IMPAIRS ANTIGEN-SPECIFIC T-CELL RESPONSES [J].
COLLINS, HL ;
BANCROFT, GJ .
INFECTION AND IMMUNITY, 1991, 59 (11) :3883-3888
[6]   IMPAIRMENT OF RAW 264.7 MACROPHAGE FUNCTION BY ANTIARRHYTHMIC DRUGS [J].
DAS, KC ;
MISRA, HP .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1994, 132 (02) :151-162
[7]   OPSONIC REQUIREMENTS FOR THE UPTAKE OF CRYPTOCOCCUS-NEOFORMANS BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES [J].
DAVIES, SF ;
CLIFFORD, DP ;
HOIDAL, JR ;
REPINE, JE .
JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (06) :870-874
[8]  
DELPRETE G, 1993, J IMMUNOL, V150, P353
[9]  
DESHAW M, 1995, CLIN EXP IMMUNOL, V99, P425, DOI 10.1111/j.1365-2249.1995.tb05568.x
[10]   Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model [J].
Devi, SJN .
VACCINE, 1996, 14 (09) :841-844